Vanda sues FDA over 'unnecessary' dog testing requirement

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) filed suit against FDA requesting a federal court lift a partial clinical hold the agency placed on tradipitant after Vanda refused to conduct a nine-month dog toxicity study.

In an open letter, Vanda called on drug companies to join it in

Read the full 453 word article

User Sign In